ABC Heart Fail Cardiomyop 2022; 2(4): 335-342
Asymptomatic Ventricular Dysfunction and HFrEF Secondary to Classic Chemotherapy
Monica S. Avila
, Deborah de Sá Pereira Belfort, Silvia Marinho Martins, Ludhmila Abrahão Hajjar
Introduction
Advances in oncology, such as better access to the health care system, earlier cancer diagnosis, and new chemotherapies, have led to longer survival of patients with cancer over the last decades. However, this population is vulnerable to drug-related adverse cardiovascular events, like cardiomyopathy, which leads to heart failure and impairs survival and quality of life., Among different classes of chemotherapeutic agents, classically anthracyclines and trastuzumab stand out as the most related to cardiomyopathy. Anthracyclines may cause cardiac dysfunction in cancer survivals in 9% of cases depending on risk factors and cumulative dose, and trastuzumab may cause it in 18.6% of cases with adjuvant chemotherapy.,
[…]
Keywords: Anthracyclines; Cardiotoxicity; Heart Failure; Trastuzumab
357
